MSTX Pengajuan SEC - Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	549300DQ13KM0J4E2H36
CIK	1160308

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

September 2, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 2, 2025 SAVARA INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 2, 2025 SAVARA INC.
September 2, 2025	EX-99.1	Safe Harbor Statement © Savara Inc. All Rights Reserved. Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by EX-99.1 Corporate Overview Developing New Therapies for Rare Respiratory Diseases September 2025 © Savara Inc. All Rights Reserved. Exhibit 99.1 Safe Harbor Statement © Savara Inc. All Rights Reserved. Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the
August 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc.
June 6, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 5, 2025 SAVARA INC.
May 27, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 27, 2025 SAVARA INC.
May 27, 2025	EX-99.1	SAVARA RECEIVES REFUSAL TO FILE (RTF) LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR THE BIOLOGICS LICENSE APPLICATION (BLA) FOR MOLBREEVI* TO TREAT PATIENTS WITH AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP) EX-99.1 Exhibit 99.1 SAVARA RECEIVES REFUSAL TO FILE (RTF) LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR THE BIOLOGICS LICENSE APPLICATION (BLA) FOR MOLBREEVI* TO TREAT PATIENTS WITH AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP) LANGHORNE, Pa. — May 27, 2025 — Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory
May 13, 2025	EX-3.1	Composite Amended and Restated Certificate of Incorporation, as amended, of the Registrant. Exhibit 3.1 MAST THERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Mast Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows. 1.
May 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc
May 13, 2025	EX-10.1	Loan and Security Agreement, dated March 26, 2025, between the Company and the lenders party thereto and Hercules Capital, Inc., as administrative agent and collateral agent. Exhibit 10.1 Certain identified information in this document has been excluded because it is both (i) not material and (ii) is the type the registrant treats as private or confidential. [***] indicates where such information has been omitted. Certain information contained in this exhibit has been redacted where indicated because disclosure of such information would constitute a clearly unwarranted
April 25, 2025	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 mt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-
April 25, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by
April 25, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru
April 25, 2025	EX-19.1	Insider Trading and Disclosure Policy. Exhibit 19.1 Savara Inc. Insider Trading and Disclosure Policy This Insider Trading and Disclosure Policy (this “Policy”) sets forth the policy of Savara Inc. (f/k/a Mast Therapeutics, Inc.) (the “Company”) regarding transactions by certain individuals and entities involving securities of the Company and, where applicable, the disclosure of such transactions. All references to the “Company” in thi
March 31, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 31, 2025 SAVARA INC.
March 27, 2025	EX-10.40	Amended and Restated Executive Employment Agreement, dated March 13, 2025, between Savara Inc. and Kathleen McCabe. Exhibit 10.40 SAVARA INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into as of March 13, 2025 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Kathleen McCabe (“Executive”). This Agreement amends and restates and supersedes in its entirety the Amended and Restated Executive Employm
March 27, 2025	EX-10.39	Executive Employment Agreement, dated August 24, 2023, between Savara Inc. and Anne Erickson. Exhibit 10.39 SAVARA INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of August 1, 2023 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Anne Erickson (“Executive”). WHEREAS, the Company desires to employ Executive as the Company’s Chief Business Officer pursuant to the terms of this Agreement. NOW, THEREFORE, in con
March 27, 2025	EX-10.41	Master Services Agreement by and between Savara ApS and Selvita S.A., effective January 17, 2024. Exhibit 10.41 Certain identified information in this document has been excluded because it is both (i) not material and (ii) is the type the registrant treats as private or confidential. [***] indicates where such information has been omitted. MASTER SERVICES AGREEMENT This Master Service Agreement (the “Agreement”) is made effective as of 17.01.2024 (“Effective Date”), by and between: SELVITA S.A
March 27, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K mt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc.
March 27, 2025	EX-10.38	Executive Employment Agreement, dated October 15, 2024, between Savara Inc. and Braden Parker. Exhibit 10.38 SAVARA INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of October 15, 2024 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Braden Parker (“Executive”). WHEREAS, the Company desires to employ Executive as the Company’s Chief Commercial Officer pursuant to the terms of this Agreement. NOW, THEREFORE, in
March 26, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 26, 2025 SAVARA INC. (Exact na UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 26, 2025 SAVARA INC.
March 26, 2025	EX-99.1	SAVARA ENTERS INTO NON-DILUTIVE DEBT FINANCING FOR UP TO $200M WITH HERCULES CAPITAL — Includes $30M at Close to Refinance Existing Debt Facility — Exhibit 99.1 SAVARA ENTERS INTO NON-DILUTIVE DEBT FINANCING FOR UP TO $200M WITH HERCULES CAPITAL — Includes $30M at Close to Refinance Existing Debt Facility — LANGHORNE, PA – March 26, 2025 – Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with Hercule
February 14, 2025	EX-99.1 JOINT FILING	JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 JOINT FILING 2 p25-0485exhibit991.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the ne
February 11, 2025	EX-1	JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) EX-1 2 jas.htm JOINT ACQUISITION STATEMENT EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing addi
February 10, 2025	EX-99	JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Savara Inc.
January 23, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 23, 2025 SAVARA INC.
January 13, 2025	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 13, 2025 SAVARA INC.
January 13, 2025	EX-99.1	Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” Exhibit 99.1 Corporate Overview Developing New Therapies for Rare Respiratory Diseases January 2025 © Savara Inc. All Rights Reserved. Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “pla
November 27, 2024	EX-99.A	AGREEMENT EX-99.A 2 d891757dex99a.htm EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Savara Inc. Date: November 27, 2024 FRAZIER LIFE SCIENCES PUBLIC FUND, L.P. B
November 27, 2024	SC 13G	SVRA / Savara Inc. / Frazier Life Sciences Public Fund, L.P. - SC 13G Passive Investment SC 13G 1 d891757dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Savara Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 805111101 (CUSIP Number) November 20, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
November 14, 2024	SC 13G/A	SVRA / Savara Inc. / PRUDENTIAL FINANCIAL INC Passive Investment SC 13G/A 1 finsavara.htm DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment # 1 Name of Issuer: SAVARA INC Title of Class of Securities: Common Stock CUSIP Number: 805111101 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROUP: (a) N/A
November 12, 2024	EX-10.3	EX-10.3 Exhibit 10.3 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN NONQUALIFIED STOCK OPTION AWARD Savara Inc., a Delaware corporation (the “Company”) hereby grants the following Non-Qualified Stock Option award pursuant to its 2024 Omnibus Incentive Plan (the “Plan”). The terms of the grant are set forth in the attached Nonqualified Stock Option Award Agreement (the “Agreement”). NOTICE OF GRANT Participant: [
November 12, 2024	EX-10.2	EX-10.2 Exhibit 10.2 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN INCENTIVE STOCK OPTION AWARD Savara Inc., a Delaware corporation (the “Company”) hereby grants the following Incentive Stock Option award pursuant to its 2024 Omnibus Incentive Plan (the “Plan”). The terms of the grant are set forth in the attached Incentive Stock Option Award Agreement (the “Agreement”). NOTICE OF GRANT Participant: [] Date of
November 12, 2024	EX-10.4	EX-10.4 Exhibit 10.4 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD Savara Inc., a Delaware corporation (the “Company”) hereby grants the following Restricted Stock Unit award pursuant to its 2024 Omnibus Incentive Plan (the “Plan”). The terms of the grant are set forth in the attached Restricted Stock Unit Award Agreement (the “Agreement”). NOTICE OF GRANT Participant: [] Date of Gra
November 12, 2024	EX-10.3	Form of Nonqualified Stock Option Award Agreement under the 2024 Omnibus Incentive Plan. Exhibit 10.3 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN NONQUALIFIED STOCK OPTION AWARD Savara Inc., a Delaware corporation (the “Company”) hereby grants the following Non-Qualified Stock Option award pursuant to its 2024 Omnibus Incentive Plan (the “Plan”). The terms of the grant are set forth in the attached Nonqualified Stock Option Award Agreement (the “Agreement”). NOTICE OF GRANT Participant: [
November 12, 2024	EX-10.2	Form of Incentive Stock Option Award Agreement under the 2024 Omnibus Incentive Plan. Exhibit 10.2 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN INCENTIVE STOCK OPTION AWARD Savara Inc., a Delaware corporation (the “Company”) hereby grants the following Incentive Stock Option award pursuant to its 2024 Omnibus Incentive Plan (the “Plan”). The terms of the grant are set forth in the attached Incentive Stock Option Award Agreement (the “Agreement”). NOTICE OF GRANT Participant: [] Date of
November 12, 2024	SC 13G/A	SVRA / Savara Inc. / Adage Capital Management, L.P. - SAVARA INC. Passive Investment SC 13G/A 1 p24-3026sc13ga.htm SAVARA INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) September 30, 2024** (Date of Event Which Requires Filing of This Statement) Check the appropriate
November 12, 2024	EX-10.4	Form of Restricted Stock Unit Award Agreement under the 2024 Omnibus Incentive Plan. Exhibit 10.4 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD Savara Inc., a Delaware corporation (the “Company”) hereby grants the following Restricted Stock Unit award pursuant to its 2024 Omnibus Incentive Plan (the “Plan”). The terms of the grant are set forth in the attached Restricted Stock Unit Award Agreement (the “Agreement”). NOTICE OF GRANT Participant: [] Date of Gra
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara
November 12, 2024	EX-3.1	Savara Inc. Certificate of Amendment to Amended and Restated Certificate of Incorporation. Exhibit 3.1 MAST THERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Mast Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows. 1.
November 8, 2024	EX-99	JOINT FILING AGREEMENT EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Savara Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the
November 8, 2024	SC 13G	SVRA / Savara Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Savara Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 805111101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
November 6, 2024	SC 13G/A	SVRA / Savara Inc. / Farallon Capital Partners, L.P. Passive Investment SC 13G/A 1 savara13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8) * Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (Cusip Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to
October 1, 2024	EX-4.1	Savara Inc. 2021 Inducement Equity Incentive Plan, as amended Exhibit 4.1 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended through September 17, 2024) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of the
October 1, 2024	S-8	As filed with the Securities and Exchange Commission on October 1, 2024 As filed with the Securities and Exchange Commission on October 1, 2024 Registration No.
October 1, 2024	EX-FILING FEES	Filing fee table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Aggregate Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock (par
August 14, 2024	SC 13D/A	SVRA / Savara Inc. / Growth Equity Opportunities 17, LLC - GROWTH EQUITY OPPORTUNITIES 17, LLC / SAVARA INC -- 13D/A(#2) Activist Investment SC 13D/A 1 geo17-savara18865.htm GROWTH EQUITY OPPORTUNITIES 17, LLC / SAVARA INC - 13D/A(#2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Savara Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 805111101 (CUSIP Number) Stephanie Brecher New Enterprise Associates
August 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc.
July 26, 2024	S-8	As filed with the Securities and Exchange Commission on July 26, 2024 As filed with the Securities and Exchange Commission on July 26, 2024 Registration No.
July 26, 2024	EX-FILING FEES	Filing fee table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Aggregate Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock (par value $0
July 8, 2024	SC 13G/A	SVRA / Savara Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us8051111016070824.txt us8051111016070824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) SAVARA INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 805111101 - (CUSIP Number) June 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat
June 28, 2024	EX-1.1	Underwriting Agreement, dated June 27, 2024, by and among Savara Inc., Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein Exhibit 1.1 26,246,720 Shares of Common Stock Savara Inc. UNDERWRITING AGREEMENT June 27, 2024 JEFFERIES LLC PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o PIPER SANDLER & CO. 800 Nicollet Mall, Suite 800 Minneapolis, Minnesota 55402 Ladies and Gentlemen: Introductory. Savara Inc., a Delaware corporation (the “Co
June 28, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 27, 2024 SAVARA INC.
June 28, 2024	EX-99.1	SAVARA ANNOUNCES PRICING OF $100.0 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK Exhibit 99.1 SAVARA ANNOUNCES PRICING OF $100.0 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK LANGHORNE, Pa., June 28, 2024— Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its common stock at a price of $3.81 per share before deducting underwriting discounts
June 28, 2024	424B5	26,246,720 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279274 PROSPECTUS SUPPLEMENT (To Prospectus dated May 21, 2024) 26,246,720 Shares of Common Stock We are offering 26,246,720 shares of our common stock, $0.001 par value per share, in this offering. Our common stock is traded on The Nasdaq Global Select Market under the symbol “SVRA.” On June 27, 2024, the last reported sales
June 26, 2024	EX-99.1	SAVARA ANNOUNCES MOLGRAMOSTIM NEBULIZER SOLUTION (MOLGRAMOSTIM) ACHIEVED STATISTICAL SIGNIFICANCE FOR PRIMARY ENDPOINT AND MULTIPLE SECONDARY ENDPOINTS IN IMPALA-2, A PIVOTAL PHASE 3 CLINICAL TRIAL IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) EX-99.1 Exhibit 99.1 SAVARA ANNOUNCES MOLGRAMOSTIM NEBULIZER SOLUTION (MOLGRAMOSTIM) ACHIEVED STATISTICAL SIGNIFICANCE FOR PRIMARY ENDPOINT AND MULTIPLE SECONDARY ENDPOINTS IN IMPALA-2, A PIVOTAL PHASE 3 CLINICAL TRIAL IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) • Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus Pl
June 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 26, 2024 SAVARA INC. (Exact nam UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 26, 2024 SAVARA INC.
June 10, 2024	EX-10.1	Savara Inc. 2024 Omnibus Incentive Plan EX-10.1 Exhibit 10.1 SAVARA INC. 2024 OMNIBUS INCENTIVE PLAN 1. PURPOSE OF THE PLAN. The purpose of the 2024 Omnibus Incentive Plan (the “Plan”) is to provide favorable opportunities for directors, officers, employees, consultants or advisors employed by or providing services to Savara Inc., a Delaware corporation (the “Company”) or any of its Subsidiaries, to acquire shares of common stock of the
June 10, 2024	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2024 SAV UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.
June 7, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2024 SAVARA INC.
June 7, 2024	EX-3.1	Savara Inc. Certificate of Amendment to Amended and Restated Certificate of Incorporation Exhibit 3.1 SAVARA INC. CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Savara Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify that: 1. The name of the Corporation is Savara Inc. 2. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the St
May 20, 2024	CORRESP	SAVARA, INC. 1717 Langhorne Newtown Road, Suite 303 Langhorne, PA 19047 SAVARA, INC. 1717 Langhorne Newtown Road, Suite 303 Langhorne, PA 19047 May 20, 2024 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC, 20549 Re: Savara, Inc. Acceleration Request Registration Statement on Form S-3 File No. 333-279274 Dear Sir/Madam: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Securities Act”),
May 9, 2024	EX-10.1	Master Services Agreement (the “Agreement”), dated February 13, 2024, by and between Fujifilm Diosynth Biotechnologies UK Limited, Fujifilm Diosynth Biotechnologies Texas, LLC, and Fujifilm Diosynth Biotechnologies U.S.A., Inc. and Savara Inc. Exhibit 10.1 Certain identified information in this document has been excluded because it is both (i) not material and (ii) is the type the registrant treats as private or confidential. [***] indicates where such information has been omitted. (1) FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED (2) FUJIFILM DIOSYNTH BIOTECHNOLOGIES TEXAS, LLC (3) FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC. AND (4)
May 9, 2024	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) SAVARA INC.
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc
May 9, 2024	S-3	As filed with the Securities and Exchange Commission on May 9, 2024 Table of Contents As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.
April 26, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
April 26, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by
April 12, 2024	8-K	Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 10, 2024 SAVARA INC.
April 12, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by
April 12, 2024	SC 13D/A	SVRA / Savara Inc. / Bain Capital Life Sciences Fund II, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.
March 7, 2024	EX-97	Clawback Policy Exhibit 97 SAVARA INC. POLICY REGARDING THE MANDATORY RECOVERY OF COMPENSATION EFFECTIVE NOVEMBER 28, 2023 I. Applicability. This Policy Regarding the Mandatory Recovery of Compensation (the “Policy”) applies to any Incentive Compensation paid to Savara Inc.’s (the “Company”) Executive Officers. The Policy is intended to comply with and be interpreted in accordance with the requirements of Listing
March 7, 2024	EX-FILING FEES	Filing fee table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Aggregate Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock (par value $0
March 7, 2024	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. (Ex
March 7, 2024	EX-10.36	Amendment No. 2 to the Manufacture and Supply Agreement, dated December 13, 2023 entered into by and between Savara ApS GEMABIOTECH SAU Exhibit 10.36 Certain identified information in this document has been excluded because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates where such information has been omitted. AMENDMENT No. 2 TO MANUFACTURE AND SUPPLY AGREEMENT This Amendment No. 2 to the Manufacture and Supply Agreement (“Amendment No. 2”), dated December 13, 2023 (
March 7, 2024	EX-4.1	Savara Inc. 2021 Inducement Equity Incentive Plan, as amended Exhibit 4.1 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended through February 2024) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of the Comp
March 7, 2024	S-8	Power of Attorney is contained on the signature page As filed with the Securities and Exchange Commission on March 7, 2024 Registration No.
February 16, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2024 SAVARA INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2024 SAVARA INC.
February 14, 2024	SC 13G/A	SVRA / Savara Inc. / Zambon Spa - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Savara Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) January 24, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu
February 14, 2024	SC 13G/A	SVRA / Savara Inc. / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246235d19sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the
February 13, 2024	SC 13G	SVRA / Savara Inc. / PRUDENTIAL FINANCIAL INC Passive Investment SC 13G 1 sav.htm DOCUMENT TYPE SC 13G TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Name of Issuer: SAVARA INC Title of Class of Securities: Common Stock CUSIP Number: 805111101 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROUP: (a) N/A (b) N/A 3) SEC USE ONLY
February 13, 2024	SC 13G/A	SVRA / Savara Inc. / CAXTON CORP Passive Investment SC 13G/A 1 d1096525013g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Savara Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box
February 7, 2024	SC 13G/A	SVRA / Savara Inc. / ADAGE CAPITAL PARTNERS GP, L.L.C. - SAVARA INC. Passive Investment SC 13G/A 1 p24-0475sc13ga.htm SAVARA INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate bo
February 1, 2024	SC 13G/A	SVRA / Savara Inc. / Farallon Capital Partners, L.P. Passive Investment SC 13G/A 1 svra13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7) * Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (Cusip Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to de
January 25, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 25, 2024 SAVARA INC.
January 5, 2024	EX-99.1	Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” EX-99.1 Exhibit 99.1 Corporate Overview Developing New Therapies for Rare Respiratory Diseases January 2024 Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “plan,” “anticipate,” “believe,
January 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 5, 2024 SAVARA INC. (Exact n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 5, 2024 SAVARA INC.
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara
August 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc.
July 26, 2023	SC 13D/A	SVRA / Savara Inc / Growth Equity Opportunities 17, LLC - GROWTH EQUITY OPPORTUNITIES 17, LLC / SAVARA INC -- 13D/A(#1) Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Savara, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 805111101 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name,
July 25, 2023	EX-99.1	Joint Filing Agreement. Exhibit 1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement.
July 25, 2023	SC 13G	SVRA / Savara Inc / TCG Crossover GP I, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Savara Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 805111101 (CUSIP Number) July 17, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to wh
July 19, 2023	SC 13D/A	SVRA / Savara Inc / Bain Capital Life Sciences Fund II, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.
July 19, 2023	EX-99.H	AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D EX-99.H Exhibit H AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, as amended, to file this Schedule 13D (including amendments thereto) joi
July 13, 2023	424B5	21,000,000 Shares of Common Stock Pre-Funded Warrants to Purchase 5,666,667 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257709 PROSPECTUS SUPPLEMENT (To Prospectus dated July 16, 2021) 21,000,000 Shares of Common Stock Pre-Funded Warrants to Purchase 5,666,667 Shares of Common Stock We are offering 21,000,000 shares of our common stock, $0.001 par value per share, in this offering. We are also offering to certain of our existing large inv
July 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 12, 2023 SAVARA INC. (Exact nam UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 12, 2023 SAVARA INC.
July 13, 2023	EX-1.1	Underwriting Agreement, dated July 12, 2023, by and among Savara Inc., Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein EX-1.1 Exhibit 1.1 21,000,000 Shares of Common Stock and Pre-Funded Warrants to Purchase 5,666,667 Shares of Common Stock Savara Inc. UNDERWRITING AGREEMENT July 12, 2023 JEFFERIES LLC PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o PIPER SANDLER & CO. 800 Nicollet Mall, Suite 800 Minneapolis, Minnesota 55402 Ladi
July 13, 2023	EX-99.1	SAVARA ANNOUNCES PRICING OF $80 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS EX-99.1 Exhibit 99.1 SAVARA ANNOUNCES PRICING OF $80 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS LANGHORNE, Pennsylvania – July 13, 2023 – Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 21,000,000 shares of its common stock at a price of $3.00 per share
July 13, 2023	EX-4.1	Form of Pre-Funded Warrant (Incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on July 13, 2023). EX-4.1 Exhibit 4.1 SAVARA INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [•] Number of Shares: [•] (subject to adjustment) Original Issue Date: July 17, 2023 Savara Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitted registered assigns (the
June 16, 2023	S-8	As filed with the Securities and Exchange Commission on June 16, 2023 S-8 As filed with the Securities and Exchange Commission on June 16, 2023 Registration No.
June 16, 2023	EX-4.1	Savara Inc. 2021 Inducement Equity Incentive Plan, as amended EX-4.1 Exhibit 4.1 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended through June 8, 2023) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of th
June 16, 2023	EX-FILING FEES	Filing fee table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc.
June 9, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2023 SAVARA INC.
June 8, 2023	EX-99.1	© Savara Inc. All Rights Reserved. Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by EX-99.1 Corporate Overview Developing New Therapies for Rare Respiratory Diseases June 2023 Exhibit 99.1 © Savara Inc. All Rights Reserved. Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,”
June 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2023 SAVARA INC. (Exact name UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2023 SAVARA INC.
May 15, 2023	EX-10	First Amendment to Lease Agreement, dated February 28, 2023, between Savara Inc. and 1717 OSSRE, LLC. (Incorporated by reference to Exhibit 10.1 of the Registrant's Quarterly Report on Form 10-Q filed on May 15, 2023.) Exhibit 10.2 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE (this “Amendment”) is made this 28th day of February, 2023 (the “Effective Date”), by and between 1717 OSSRE, LLC, a Pennsylvania limited liability company (“Landlord”), and SAVARA INC., a Delaware corporation (“Tenant”). BACKGROUND A. Landlord and Tenant entered into a certain written Agreement of Lease dated July 7, 2021 (the “O
May 15, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc
May 15, 2023	EX-10	Lease Agreement, dated July 7, 2021, between Savara Inc. and 1717 OSSRE, LLC. (Incorporated by reference to Exhibit 10.1 of the Registrant's Quarterly Report on Form 10-Q filed on May 15, 2023.) LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”), effective as of the 7th day of July, 2021 (the “Effective Date”), is made by and between 1717 OSSRE, LLC, a Pennsylvania limited liability company (“Landlord”), and SAVARA INC.
April 28, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru
April 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 30, 2023	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. (Ex
March 30, 2023	EX-21	List of Subsidiaries (Incorporated by reference to Exhibit 21.1 to the Registrant’s Annual Report on Form 10-K filed on March 30, 2023. Exhibit 21.1 Savara Inc. List of Subsidiaries Name Ownership % Aravas Inc. 100% Savara ApS 100% Drugrecure A/S 100% Pharmaorigin A/S 100% SD Pharmaceuticals, Inc. 100% Aires Pharmaceuticals, Inc. 100%
March 30, 2023	EX-10	First Amendment to Lease Agreement, dated October 26, 2022, between the Registrant and Overlook at Rob Roy Owner, LLC. Exhibit 10.29 DocuSign Envelope ID: 8B2E51B6-69B8-42A7-9E84-016D2871D63E October 26, 2022 FIRST AMENDMENT TO LEASE AGREEMENT Re: Lease Agreement dated May 11, 2021, by and between Overlook at Rob Roy Owner, LLC, as Lessor, and Savara, Inc., as Lessee, consisting of approximately 2,260 rentable square feet of space locally known as Suite III- 201 at 6836 Bee Caves Road, Austin, Travis County, Texas
March 30, 2023	EX-4.1	Savara Inc. Amended and Restated 2015 Omnibus Incentive Plan, as amended EX-4.1 Exhibit 4.1 SAVARA INC. AMENDED AND RESTATED 2015 OMNIMBUS INCENTIVE PLAN (as amended by the Board through March 8, 2023, subject to stockholder approval) Savara Inc., a Delaware corporation (f/k/a Mast Therapeutics, Inc., the “Company”), hereby establishes the amended and restated 2015 Omnibus Incentive Plan (the “Plan”), effective as of the Effective Date. 1. PURPOSE OF THIS PLAN The purp
March 30, 2023	S-8	As filed with the Securities and Exchange Commission on March 30, 2023 S-8 As filed with the Securities and Exchange Commission on March 30, 2023 Registration No.
March 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 28, 2023 SAVARA INC. (Exact na UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 28, 2023 SAVARA INC.
March 30, 2023	EX-FILING FEES	Filing fee table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc.
March 30, 2023	EX-10	Amendment No. 1 to the Manufacture and Supply Agreement, dated December 7, 2022 entered into by and between Savara ApS and GEMABIOTECH SAU (Incorporated by reference to Exhibit 10.33 to the Registrant’s Annual Report on Form 10-K filed on March 30, 2023.) Exhibit 10.33 Certain identified information in this document has been excluded because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates where such information has been omitted. AMENDMENT No. 1 TO MANUFACTURE AND SUPPLY AGREEMENT This Amendment No. 1 to the Manufacture and Supply Agreement (“Amendment No. 1”), dated December 7, 2022 (“
March 30, 2023	EX-10	Executive Employment Agreement, dated November 10, 2022, between Savara Inc. and Raymond D. Pratt, M.D. (Incorporated by reference to Exhibit 10.34 to the Registrant’s Annual Report on Form 10-K filed on March 30, 2023.) Exhibit 10.34 SAVARA INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of November 10, 2022 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Raymond D. Pratt, M.D. (“Executive”). WHEREAS, the Company desires to employ Executive as the Company’s Chief Medical Officer pursuant to the terms of this Agreement. NOW, THEREF
March 30, 2023	EX-4.2	Savara Inc. 2021 Inducement Equity Incentive Plan, as amended EX-4.2 Exhibit 4.2 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended through March 8, 2023) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of t
March 30, 2023	EX-3.1	Amended and Restated Bylaws of Savara, Inc., dated March 28, 2023 (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on March 30, 2023). EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF SAVARA INC. (a Delaware corporation) March 28, 2023 ARTICLE I CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of Savara Inc. (the “corporation”) shall be fixed in the Certificate of Incorporation of the corporation. 1.2 OTHER OFFICES. The board of directors may at any time establish the principal office and any branch or subordinate
March 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 10, 2023 SAVARA INC. (Exact na UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 10, 2023 SAVARA INC.
March 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2023 SAVARA INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2023 SAVARA INC.
February 14, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2023 SAVARA INC.
February 14, 2023	SC 13G/A	SVRA / Savara Inc / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236584d5sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the a
February 14, 2023	EX-10.1	Executive Employment Agreement, dated February 13, 2023, between Savara Inc. and Rob Lutz (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on February 13, 2023.) Exhibit 10.1 SAVARA INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of February 13, 2023 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Rob Lutz (“Executive”). WHEREAS, the Company desires to employ Executive as the Company’s Chief Operating Officer pursuant to the terms of this Agreement. NOW, THEREFORE, in consi
January 20, 2023	EX-4.1	Savara Inc. 2021 Inducement Equity Incentive Plan (Incorporated by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-8 filed on January 20 2023.) EX-4.1 Exhibit 4.1 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended through December 13, 2022) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary
January 20, 2023	EX-FILING FEES	Filing fee table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Aggregate Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock (par value $0
January 20, 2023	S-8	As filed with the Securities and Exchange Commission on January 20, 2023 S-8 As filed with the Securities and Exchange Commission on January 20, 2023 Registration No.
December 15, 2022	EX-10.2	Amended and Restated Executive Employment Agreement, dated December 13, 2022, between Savara Inc. and David Lowrance (Incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on December 15, 2022.) Exhibit 10.2 SAVARA INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the ?Agreement?) is entered into as of December 13, 2022 (the ?Effective Date?) by and between Savara Inc. (the ?Company?), and David Lowrance (?Executive?). This Agreement amends and restates and supersedes in its entirety the Executive Employment Agreement dated
December 15, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 13, 2022 SAVARA INC.
December 15, 2022	EX-10.1	Amended and Restated Executive Employment Agreement, dated December 13, 2022, between Savara Inc. and Matthew Pauls (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on December 15, 2022.) Exhibit 10.1 SAVARA INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the ?Agreement?) is entered into as of December 13, 2022 (the ?Effective Date?) by and between Savara Inc. (the ?Company?), and Matthew Pauls (?Executive?). This Agreement amends and restates and supersedes in its entirety the Amended and Restated Executive Employm
November 21, 2022	S-8	As filed with the Securities and Exchange Commission on November 21, 2022 S-8 As filed with the Securities and Exchange Commission on November 21, 2022 Registration No.
November 21, 2022	EX-4.1	Savara Inc. 2021 Inducement Equity Incentive Plan, as amended EX-4.1 Exhibit 4.1 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended September 1, 2021 and September 8, 2022) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent
November 21, 2022	EX-FILING FEES	Filing fee table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc.
November 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara
August 26, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 24, 2022 SAVARA INC.
August 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc.
June 3, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 2, 2022 SAVARA INC.
May 11, 2022	EX-10.1	Amended and Restated Loan and Security Agreement, dated April 21, 2022, between the Registrant and its subsidiary, Aravas Inc., as borrowers, and Silicon Valley Bank (Incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q filed on May 11, 2022.) Exhibit 10.1 AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this ?Agreement?) is dated as of the Effective Date between SILICON VALLEY BANK, a California corporation (?Bank?), and the borrower listed on Schedule I hereto (?Borrower?), and provides the terms on which Bank shall lend to Borrower, and Borrower shall repay Bank. This Agreement a
May 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc
April 22, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 21, 2022 SAVARA INC.
April 19, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14
April 19, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6
March 30, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. (Ex
March 30, 2022	S-8	Power of Attorney is contained on the signature page. As filed with the Securities and Exchange Commission on March 30, 2022 Registration No.
March 30, 2022	EX-10.17	Form of Restricted Stock Unit Agreement (Inducement Award) – Under the 2021 Inducement Equity Incentive Plan (Incorporated by reference to Exhibit 10.17 to the Registrant’s Annual Report on Form 10-K filed on March 30, 2022.) Exhibit 10.17 SAVARA INC. RESTRICTED STOCK UNIT AGREEMENT (INDUCEMENT AWARD) NOTICE OF GRANT OF RESTRICTED STOCK UNITS The Awardee has been granted an award of Restricted Stock Units (the ?Award?) pursuant to this Agreement and the Savara Inc. 2021 Inducement Equity Plan (the ?Plan?), each of which represents the right to receive on the applicable Settlement Date one (1) Share of common stock of S
March 30, 2022	EX-10.16	Form of Non-Statutory Stock Option Agreement – Under the 2021 Inducement Equity Incentive Plan (Incorporated by reference to Exhibit 10.16 to the Registrant’s Annual Report on Form 10-K filed on March 30, 2022.) Exhibit 10.16 SAVARA INC. NON-STATUTORY STOCK OPTION AGREEMENT (INDUCEMENT AWARD) THIS NON-STATUTORY STOCK OPTION GRANT AGREEMENT (this ?Agreement?), effective as of [?] (the ?Grant Date?), is entered into by and between Savara Inc., a Delaware corporation (the ?Company?), and [?] (the ?Grantee?). 1. Grant of Option. The Company hereby grants to the Grantee a non-statutory stock option (the ?Optio
March 30, 2022	EX-FILING FEES	Filing fee table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Savara Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Aggregate Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock (par value $0
March 30, 2022	EX-4.2	Savara Inc. 2021 Inducement Equity Incentive Plan, as amended Exhibit 4.2 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021, as amended September 1, 2021) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals? entering into employment with the Company or any Parent or Subsidiary of the Company.
March 30, 2022	EX-21.1	List of Subsidiaries Exhibit 21.1 Savara Inc. List of Subsidiaries Name Ownership % Aravas Inc. 100% Savara ApS 100% Drugrecure A/S 100% Pharmaorigin A/S 100% Savara Australia Pty Limited 100% Aires Pharmaceuticals, Inc. 100% SD Pharmaceuticals, Inc. 100%
February 14, 2022	SC 13G/A	SVRA / Savara Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Savara Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
February 14, 2022	SC 13G/A	SVRA / Savara Inc / CAXTON CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 10, 2022	SC 13G/A	SVRA / Savara Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - SAVARA INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which
January 13, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 13, 2022 SAVARA INC.
January 10, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 10, 2022 SAVARA INC.
January 10, 2022	EX-99.1	© Savara Inc. All Rights Reserved. Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by Corporate Overview Developing New Therapies for Rare Respiratory Diseases January 2022 Exhibit 99.
November 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara
August 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc.
July 14, 2021	CORRESP	Savara Inc. 6836 Bee Cave Road Building III, Suite 200 Austin, TX 78746 July 14, 2021 Savara Inc. 6836 Bee Cave Road Building III, Suite 200 Austin, TX 78746 July 14, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Savara Inc. Registration Statement on Form S-3 Filed July 6, 2021 File No. 333-257709 Acceleration Request Requested Date: July 16, 2021 Requested Time: 4:00 p.m. (Eastern time), or as soon t
July 7, 2021	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 2, 2021 SAVARA INC.
July 6, 2021	EX-3.1	Composite Amended and Restated Certificate of Incorporation, as amended, of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Registration Statement on Form S-3 filed on July 6, 2021.) Exhibit 3.1 MAST THERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Mast Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), does hereby certify as follows. 1.
July 6, 2021	EX-1.2	Sales Agreement, dated July 6, 2021, between the Registrant and Evercore Group L.L.C. (Incorporated by reference to Exhibit 1.2 of the Registrant’s Registration Statement on Form S-3 filed on July 6, 2021.) Exhibit 1.2 Execution Version SAVARA INC. SHARES OF COMMON STOCK (PAR VALUE $0.001 PER SHARE) SALES AGREEMENT July 6, 2021 Evercore Group L.L.C. 55 East 52nd Street New York, NY 10055 Ladies and Gentlemen: SAVARA INC., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with EVERCORE GROUP L.L.C. (the ?Agent?) as follows: 1. Issuance and Sale of Shares. The Company ag
July 6, 2021	EX-4.1	Savara Inc. 2021 Inducement Equity Incentive Plan Exhibit 4.1 SAVARA INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted May 10, 2021) 1. Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals? entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of
July 6, 2021	S-8	As filed with the Securities and Exchange Commission on July 6, 2021 As filed with the Securities and Exchange Commission on July 6, 2021 Registration No.
July 6, 2021	EX-4.4	Form of Senior Indenture Exhibit 4.4 SAVARA INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1. Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.1. Designation and Terms of Securities 5 Section 2.2. Form of Securities and Trustee?s Certificate 7 Section 2.
July 6, 2021	S-3	As filed with the Securities and Exchange Commission on July 6, 2021 Table of Contents As filed with the Securities and Exchange Commission on July 6, 2021 Registration No.
July 6, 2021	EX-4.5	Form of Subordinated Indenture Exhibit 4.5 SAVARA INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.1 Designation and Terms of Securities 5 Section 2.2 Form of Securities and Trustee?s Certificate 7 Section
June 30, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 30, 2021 SAVARA INC.
June 14, 2021	EX-3.1	Savara Inc. Certificate of Amendment to Amended and Restated Certificate of Incorporation Exhibit 3.1 SAVARA INC. CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Savara Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), does hereby certify that: 1. The name of the Corporation is Savara Inc. 2. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the St
June 14, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 10, 2021 SAVARA INC.
June 4, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2021 SAVARA INC.
June 4, 2021	EX-10.1	Office Lease, dated June 3, 2021, between the Registrant and Overlook at Rob Roy Owner, LLC (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on June 4, 2021.) Exhibit 10.1 BASIC LEASE INFORMATION The following Basic Information is incorporated into and made a part of this lease. Each reference in this lease to any of the Basic Lease Information shall mean the respective information set forth below and shall be construed to incorporate all of the terms provided under the particular lease paragraph(s) pertaining to such information. In the event of a conf
May 13, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc
May 13, 2021	EX-10.5	Work Order under Master Services Agreement by and between Savara Inc. and Parexel International (IRL) Limited, effective January 6, 2021 (Incorporated by reference to Exhibit 10.5 of the Registrant's Quarterly Report on Form 10-Q filed on May 13, 2021.) Exhibit 10.5 Certain identified information in this document has been excluded because it is both (i) not material and (ii) is the type of information the issuer both customarily and actually treats as private and confidential. [*] indicates where such information has been omitted. Parexel Project # [*] WORK ORDER This Work Order #1 (this ?Work Order?) is by and between Savara Inc. (?Client?)
May 13, 2021	EX-10.4	Master Services Agreement by and between Savara Inc. and Parexel International (IRL) Limited, effective January 6, 2021 (Incorporated by reference to Exhibit 10.4 of the Registrant's Quarterly Report on Form 10-Q filed on May 13, 2021.) Exhibit 10.4 Certain identified information in this document has been excluded because it is both (i) not material and (ii) is the type of information the issuer both customarily and actually treats as private and confidential. [***] indicates where such information has been omitted. MASTER SERVICES AGREEMENT This Master Services Agreement (this ?Agreement?) is effective as of January 6, 2021 (the
April 27, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (a
April 27, 2021	DEF 14A	Schedule 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the
April 16, 2021	PRE 14A	- PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the
April 1, 2021	EX-10.1	Fourth Amendment, dated March 30, 2021, to Loan and Security Agreement, dated April 28, 2017, as amended on October 31, 2017, December 4, 2018 and January 31, 2021, between the Registrant, Aravas Inc. and Silicon Valley Bank (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on April 1, 2021.) Exhibit 10.1 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of March 30, 2021, by and among SILICON VALLEY BANK, a California corporation (?Bank?), SAVARA INC. f/k/a MAST THERAPEUTICS, INC., a Delaware corporation (?Parent?), and ARAVAS INC. f/k/a SAVARA INC., a Delaware corporation (each a ?Co-Borrower? an
April 1, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 30, 2021 SAVARA INC.
March 25, 2021	SC 13G	Savara Inc. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Savara Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 805111101 (CUSIP Number) March 15, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this S
March 25, 2021	SC 13D	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. __ )* Savara, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) (CUSIP Num Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Savara, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 805111101 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, A
March 19, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
March 17, 2021	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities E SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.
March 16, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 16, 2021 SAVARA INC.
March 16, 2021	EX-99.1	Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” EX-99.1 Savara Corporate Presentation (NASDAQ: SVRA) March 2021 Exhibit 99.1 Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. Suc
March 12, 2021	424B5	45,785,828 Shares of Common Stock Pre-Funded Warrants to Purchase 32,175,172 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-225994 PROSPECTUS SUPPLEMENT (To Prospectus dated July 13, 2018) 45,785,828 Shares of Common Stock Pre-Funded Warrants to Purchase 32,175,172 Shares of Common Stock We are offering 45,785,828 shares of our common stock, $0.001 par value per share, at a purchase price of $1.45 per share in this offering. We are also offering to
March 11, 2021	EX-4.1	Form of Pre-Funded Warrant (Incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on March 11, 2021.) Exhibit 4.1 SAVARA INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [?] Number of Shares: [?] (subject to adjustment) Original Issue Date: March [?], 2021 Savara Inc., a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [?] or its permitted registered assigns (the ?Hold
March 11, 2021	EX-1.1	Underwriting Agreement, dated March 11, 2021, by and among Savara Inc., Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein Exhibit 1.1 45,785,828 Shares of Common Stock and Pre-Funded Warrants to Purchase 32,175,172 Shares of Common Stock Savara Inc. UNDERWRITING AGREEMENT March 11, 2021 JEFFERIES LLC PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o PIPER SANDLER & CO. 800 Nicollet Mall, Suite 800 Minneapolis, Minnesota 55402 Ladies an
March 11, 2021	EX-10.1	Form of Warrant Repurchase Agreement (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on March 11, 2021.) Exhibit 10.1 FORM OF WARRANT REPURCHASE AGREEMENT THIS WARRANT REPURCHASE AGREEMENT (the ?Agreement?) is made and entered into as of March [?], 2021 by and among Savara Inc., a Delaware corporation (the ?Company?), and the entities listed on Exhibit A (each, a ?Seller?). WHEREAS, each Seller owns a warrant dated December 24, 2019 (the ?Warrant?) to purchase the number of shares of the Company?s Co
March 11, 2021	EX-99.1	SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK EX-99.1 Exhibit 99.1 SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AUSTIN, TX – March 11, 2021 – Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 45,785,828 shares of its common stock at a price to the public of $1.45 per share. As a component of the offering, in lieu of shares of common stock, Savara offere
March 11, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 9, 2021 SAVARA INC.
March 10, 2021	424B5	SUBJECT TO COMPLETION, DATED MARCH 10, 2021 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-225994 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to
March 10, 2021	EX-10.1	Executive Employment Agreement, dated March 9, 2021, between Savara Inc. and Badrul Chowdhury Exhibit 10.1 SAVARA INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is entered into as of March 9, 2021 (the ?Effective Date?) by and between Savara Inc. (the ?Company?), and Badrul Chowdhury (?Executive?). WHEREAS, Executive is currently employed by the Company as the Company?s Chief Medical Officer pursuant to the terms of an offer letter agreement dated
March 10, 2021	EX-10.9	Form of Incentive Stock Option Grant Agreement – Exempt Employees, in accordance with Danish employment law, under the 2015 Omnibus Incentive Plan. Exhibit 10.9 Savara Inc. 2015 Omnibus Incentive Plan Incentive Stock Option Grant Agreement ? Exempt Employees THIS INCENTIVE STOCK OPTION GRANT AGREEMENT (this ?Agreement?), effective as of [?] (the ?Grant Date?), is entered into by and between Savara Inc., a Delaware corporation (the ?Company?), and [?] (the ?Participant?). 1.Grant of Option. The Company hereby grants to the Participant [NUMBER]
March 10, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 5, 2021 SAVARA INC.
March 10, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. (Ex
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Savara Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) (CUS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Savara Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
February 12, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Savara Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) (CUS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Savara Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
January 19, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 15, 2021 SAVARA INC.
January 19, 2021	EX-99.1	Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” EX-99.1 Savara Corporate Presentation (NASDAQ: SVRA) January 2021 Exhibit 99.1 Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. S
January 6, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 31, 2020 SAVARA INC.
December 10, 2020	EX-10.1	Amended and Restated Executive Employment Agreement, dated December 8, 2020, between Savara Inc. and Matthew Pauls (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on December 10, 2020.) EX-10.1 2 d38434dex101.htm EX-10.1 Exhibit 10.1 SAVARA INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into as of December 8, 2020 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Matthew Pauls (“Executive”). This Agreement amends and restates and supersedes in its entirety the Exec
December 10, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 8, 2020 SAVARA INC.
December 10, 2020	EX-99.1	SAVARA PROVIDES PIPELINE AND BUSINESS UPDATE Announces Phase 3 AVAIL Trial Missed Primary Endpoint, Stopping Further Development of AeroVanc Appoints Matt Pauls, Chairman and Interim CEO Since September 2020, Chairman and Permanent CEO Reduces Operat Exhibit 99.1 SAVARA PROVIDES PIPELINE AND BUSINESS UPDATE Announces Phase 3 AVAIL Trial Missed Primary Endpoint, Stopping Further Development of AeroVanc Appoints Matt Pauls, Chairman and Interim CEO Since September 2020, Chairman and Permanent CEO Reduces Operating Expenses to Align with Streamlined Development Programs Discontinues Development of Apulmiq Program, Focuses Resources on Molgradex i
November 5, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara
September 11, 2020	EX-99.1	SAVARA ANNOUNCES SENIOR MANAGEMENT CHANGES Rob Neville Resigns as Chairman and Chief Executive Officer Matthew Pauls Appointed Chairman and Interim Chief Executive Officer EX-99.1 3 d34590dex991.htm EX-99.1 Exhibit 99.1 SAVARA ANNOUNCES SENIOR MANAGEMENT CHANGES Rob Neville Resigns as Chairman and Chief Executive Officer Matthew Pauls Appointed Chairman and Interim Chief Executive Officer AUSTIN, TX – Sept. 11, 2020 – Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Company’s Chief Executive Officer (CE
September 11, 2020	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 11, 2020 SAVARA INC.
September 11, 2020	EX-10.1	Executive Employment Agreement, dated September 11, 2020, between Savara Inc. and Matthew Pauls EX-10.1 2 d34590dex101.htm EX-10.1 Exhibit 10.1 Execution Version SAVARA INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of September 11, 2020 (the “Effective Date”) by and between Savara Inc. (the “Company”), and Matthew Pauls (“Executive”). WHEREAS, the Company desires to employ Executive as the Company’s Chairman and Interim CEO pursu
August 6, 2020	EX-99.1	SAVARA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Announces Final Clinical Study Design for IMPALA 2, the Next Phase 3 Study of Molgradex in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Study Expected to Start in Q EX-99.1 2 d26703dex991.htm EX-99.1 Exhibit 99.1 SAVARA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Announces Final Clinical Study Design for IMPALA 2, the Next Phase 3 Study of Molgradex in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Study Expected to Start in Q1 2021 AUSTIN, TX – August 6, 2020 – Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today
August 6, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2020 SAVARA INC.
August 6, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc.
June 1, 2020	EX-10.1	Savara Inc. Amended and Restated 2015 Omnibus Incentive Plan, as amended (Incorporated by reference to Appendix A of the Registrant’s Proxy Statement filed on April 19, 2022.) EX-10.1 2 d830249dex101.htm EX-10.1 Exhibit 10.1 SAVARA INC. AMENDED AND RESTATED 2015 OMNIBUS INCENTIVE PLAN (as amended by the Board on March 10, 2020, and approved by the stockholders on May 29, 2020) Savara Inc., a Delaware corporation (f/k/a Mast Therapeutics, Inc., the “Company”), hereby establishes the amended and restated 2015 Omnibus Incentive Plan (the “Plan”), effective as of the Effect
June 1, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 27, 2020 SAVARA INC.
May 8, 2020	DEFA14A	- DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission
May 7, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32157 Savara Inc
May 7, 2020	EX-99.1	SAVARA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Company Announces Expected Design for IMPALA 2, the Next Phase 3 Study of Molgradex in aPAP EX-99.1 2 d895900dex991.htm EX-99.1 Exhibit 99.1 SAVARA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Company Announces Expected Design for IMPALA 2, the Next Phase 3 Study of Molgradex in aPAP AUSTIN, TX – May 7, 2020 – Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the first quarter ending March 31, 2020 and provided a
May 7, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 7, 2020 SAVARA INC.
May 7, 2020	EX-10.1	License and Collaboration Agreement between Savara Inc. and Grifols, S.A, dated January 7, 2020, as amended by Amendment No. 1, dated February 18, 2020, and Amendment No. 2, dated March 31, 2020 (Incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed on May 7, 2020.) Exhibit 10.1 Certain identified information in this document has been excluded because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates where such information has been omitted. LICENSE AND COLLABORATION AGREEMENT This License and Collaboration Agreement (the “Agreement”) is entered into as of January 7, 2020 (the “Effective Date”) by a
April 30, 2020	424B3	47,927,176 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-237734 PROSPECTUS 47,927,176 Shares of Common Stock This prospectus relates to the resale from time to time of up to 47,927,176 shares of common stock of Savara Inc. by the selling stockholders listed on page 6, including their transferees, pledgees or donees or their respective successors, which consists of 9,569,430 ou
April 27, 2020	CORRESP	- CORRESP April 27, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549-3720 Attention: Tim Buchmiller Re: Savara Inc. Registration Statement on Form S-3 File No. 333-237734 Acceleration Request Requested Date: April 29, 2020 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule
April 17, 2020	S-8	SVRA / Savara Inc S-8 - - S-8 S-8 As filed with the Securities and Exchange Commission on April 17, 2020 Registration No.
April 17, 2020	S-3	SVRA / Savara Inc S-3 - - S-3 S-3 Table of Contents As filed with the Securities and Exchange Commission on April 17, 2020 Registration No.
April 17, 2020	EX-4.2	Restricted Stock Unit Agreement (Inducement Grant) between Badrul Chowdhury and Savara Inc. dated November 26, 2019. EX-4.2 Exhibit 4.2 SAVARA INC. RESTRICTED STOCK UNIT AGREEMENT (INDUCEMENT AWARD) NOTICE OF GRANT OF RESTRICTED STOCK UNITS The Awardee has been granted an award of Restricted Stock Units (the “Award”) pursuant to this Agreement, each of which represents the right to receive on the applicable Settlement Date one (1) Share of common stock of Savara Inc. (the “Company”), as follows: Awardee: Badrul
April 15, 2020	DEFA14A	SVRA / Savara Inc DEFA14A - - DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission
April 15, 2020	DEF 14A	Schedule 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 2, 2020	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 31, 2020 SAVARA INC.
March 12, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 12, 2020 SAVARA INC.
March 12, 2020	EX-10.36	Restricted Stock Unit Agreement (Inducement Grant) between Badrul Chowdhury and Savara Inc. dated November 26, 2019. EX-10.36 3 svra-ex103615.htm EX-10.36 Exhibit 10.36 SAVARA INC. NOTICE OF GRANT OF RESTRICTED STOCK UNITS The Awardee has been granted an award of Restricted Stock Units (the “Award”) pursuant to the Savara Inc. 2015 Omnibus Incentive Plan (the “Plan”), each of which represents the right to receive on the applicable Settlement Date one (1) Share of common stock of Savara Inc. (the “Company”), as f
March 12, 2020	EX-10.37	Non-statutory Stock Option Agreement (Inducement Award) between Badrul Chowdhury and Savara Inc. dated November 26, 2019 (Incorporated by reference to Exhibit 10.37 to the Registrant’s Annual Report on Form 10-K filed on March 12, 2020.) EXHIBIT 10.37 SAVARA INC. NON-STATUTORY STOCK OPTION AGREEMENT (INDUCEMENT AWARD) THIS NON-STATUTORY STOCK OPTION GRANT AGREEMENT (this “Agreement”), effective as of November 26, 2019 (the “Grant Date”), is entered into by and between Savara Inc., a Delaware corporation (the “Company”), and Badrul Chowdhury (the “Grantee”). 1.Grant of Option. The Company hereby grants to the Grantee a non-statutor
March 12, 2020	EX-99.1	SAVARA REPORTS FOURTH QUARTER / YEAR-END 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Announced Positive Results from IMPALA Open-Label Follow-Up Period That Demonstrate Continued Improvement After Longer Term Exposure to Molgradex • Company EX-99.1 2 d859106dex991.htm EX-99.1 Exhibit 99.1 SAVARA REPORTS FOURTH QUARTER / YEAR-END 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Announced Positive Results from IMPALA Open-Label Follow-Up Period That Demonstrate Continued Improvement After Longer Term Exposure to Molgradex • Company Planning an Additional Phase 3 Study of Molgradex for the Treatment of Autoimmune Pulmonary Alveolar
March 12, 2020	EX-4.25	Description of Registered Securities (Incorporated by reference to Exhibit 4.25 to the Registrant’s Annual Report on Form 10-K filed on March 12, 2020.) Exhibit 4.25 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following description of registered securities of Savara Inc. (“us,” “our,” “we” or the “Company”) is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, our amended and res
March 12, 2020	EX-10.39	Executive Employment Agreement, dated September 6, 2019, between Savara Inc. and Badrul Chowdhury, Chief Medical Officer. Exhibit 10.39 Badrul Chowdhury, MD, PhD Transmitted via email to: [email protected] Dear Badrul, Savara Inc. (“Savara’’ or “Company’’) is extremely pleased to extend to you an offer of employment with our Company as Chief Medical Officer. This offer letter and the terms contained herein supersede all other communications verbal or written. Subject to your acceptance of the terms herein, we would e
March 12, 2020	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32157 Savara Inc. (Ex
February 14, 2020	SC 13G/A	SVRA / Savara Inc / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2020	SC 13G/A	SVRA / Savara Inc / Altium Capital Management Lp - AMENDMENT TO FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Savara Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
February 14, 2020	SC 13G/A	SVRA / Savara Inc / Consonance Capital Management LP - CONSONANCE CAPITAL MANAGEMENT LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SAVARA INC (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 805111101 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 3, 2020	EX-4.1	Second Amendment to Warrant to Purchase Common Stock dated January 31, 2020, to Warrant to Purchase Common Stock of the Registrant issued to Life Science Loans II, LLC on April 28, 2017 (as amended by that certain Amendment to Warrant to Purchase Common Stock dated as of June 26, 2017) (Incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on February 3, 2020.) EX-4.1 Exhibit 4.1 SECOND AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This Second Amendment to Warrant to Purchase Common Stock (this “Amendment”) is entered into as of January 31, 2020, by and between LIFE SCIENCE LOANS II, LLC (“Holder”) and SAVARA INC. a Delaware corporation (“Company”). RECITALS Company has issued for the benefit of Holder that certain Warrant to Purchase Common Stock dated
February 3, 2020	EX-10.1	Third Amendment, dated January 31, 2020, to Loan and Security Agreement, dated April 28, 2017, as amended on October 31, 2017 and December 4, 2018, among the Registrant, Aravas Inc. and Silicon Valley Bank (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on February 3, 2020.) EX-10.1 Exhibit 10.1 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of January 31, 2020, by and among SILICON VALLEY BANK, a California corporation (“Bank”), SAVARA INC. f/k/a MAST THERAPEUTICS, INC., a Delaware corporation (“Parent”), and ARAVAS INC. f/k/a SAVARA INC., a Delaware corporation (each a “Co-Borr
February 3, 2020	EX-4.4	Amendment to Warrant to Purchase Common Stock of the Registrant dated January 31, 2020, to Warrant to Purchase Common Stock of the Registrant issued to Silicon Valley Bank on June 26, 2017 (Incorporated by reference to Exhibit 4.4 to the Registrant’s Current Report on Form 8-K filed on February 3, 2020.) EX-4.4 Exhibit 4.4 FIRST AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This First Amendment to Warrant to Purchase Common Stock (this “Amendment”) is entered into as of January 31, 2020, by and between SVB FINANCIAL GROUP (“Holder”) and SAVARA INC. a Delaware corporation (“Company”). RECITALS Company has issued for the benefit of Silicon Valley Bank (“Bank”) that certain Warrant to Purchase Common
February 3, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 31, 2020 SAVARA INC.
February 3, 2020	EX-4.5	Amendment to Warrant to Purchase Common Stock of the Registrant dated January 31, 2020, to Warrant to Purchase Common Stock of the Registrant issued to Life Science Loans II, LLC on December 4, 2018 (Incorporated by reference to Exhibit 4.5 to the Registrant’s Current Report on Form 8-K filed on February 3, 2020.) EX-4.5 Exhibit 4.5 FIRST AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This First Amendment to Warrant to Purchase Common Stock (this “Amendment”) is entered into as of January 31, 2020, by and between LIFE SCIENCE LOANS II, LLC (“Holder”) and SAVARA INC. a Delaware corporation (“Company”). RECITALS Company has issued for the benefit of Holder that certain Warrant to Purchase Common Stock dated De
February 3, 2020	EX-4.6	Amendment to Warrant to Purchase Common Stock of the Registrant dated January 31, 2020, to Warrant to Purchase Common Stock of the Registrant issued to Silicon Valley Bank on December 4, 2018 (Incorporated by reference to Exhibit 4.6 to the Registrant’s Current Report on Form 8-K filed on February 3, 2020.) EX-4.6 Exhibit 4.6 FIRST AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This First Amendment to Warrant to Purchase Common Stock (this “Amendment”) is entered into as of January 31, 2020, by and between SVB FINANCIAL GROUP (“Holder”) and SAVARA INC. a Delaware corporation (“Company”). RECITALS Company has issued for the benefit of Silicon Valley Bank (“Bank”) that certain Warrant to Purchase Common
February 3, 2020	EX-4.3	Amendment to Warrant to Purchase Common Stock of the Registrant dated January 31, 2020, to Warrant to Purchase Common Stock of the Registrant issued to Life Science Loans II, LLC on June 26, 2017 (Incorporated by reference to Exhibit 4.3 to the Registrant’s Current Report on Form 8-K filed on February 3, 2020.) EX-4.3 Exhibit 4.3 FIRST AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This First Amendment to Warrant to Purchase Common Stock (this “Amendment”) is entered into as of January 31, 2020, by and between LIFE SCIENCE LOANS II, LLC (“Holder”) and SAVARA INC. a Delaware corporation (“Company”). RECITALS Company has issued for the benefit of Holder that certain Warrant to Purchase Common Stock dated Ju
February 3, 2020	EX-4.2	Second Amendment to Warrant to Purchase Common Stock dated January 31, 2020, to Warrant to Purchase Common Stock of the Registrant issued to Silicon Valley Bank on April 28, 2017 (as amended by that certain Amendment to Warrant to Purchase Common Stock dated as of June 26, 2017) (Incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed on February 3, 2020.) EX-4.2 Exhibit 4.2 SECOND AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This Second Amendment to Warrant to Purchase Common Stock (this “Amendment”) is entered into as of January 31, 2020, by and between SVB FINANCIAL GROUP (“Holder”) and SAVARA INC. a Delaware corporation (“Company”). RECITALS Company has issued for the benefit of Silicon Valley Bank (“Bank”) that certain Warrant to Purchase Comm
January 6, 2020	SC 13G	SVRA / Savara Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Savara Inc. (Name of Issuer) Common Stock, Par Value $.001 Per Share (Title of Class of Securities) 805111101 (CUSIP Number) December 20, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
December 30, 2019	EX-99.A	AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D EX-99.A Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, as amended, to file this Schedule 13D (including amendments thereto) jo
December 30, 2019	SC 13D	SVRA / Savara Inc / Bain Capital Life Sciences Fund II, L.P. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.
December 30, 2019	EX-99.1	SAVARA GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR MOLGRADEX FOR THE TREATMENT OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (aPAP) EX-99.1 Exhibit 99.1 SAVARA GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR MOLGRADEX FOR THE TREATMENT OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (aPAP) AUSTIN, TX – Dec. 30, 2019 – Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Molgradex, an inhaled formulation of recombi
December 30, 2019	8-K	Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 23, 2019 SAVARA INC.

MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)